760957-18-4Relevant academic research and scientific papers
Design, synthesis and biological activity of new CDK4-specific inhibitors, based on fascaplysin
Aubry, Carine,Wilson, A. James,Jenkins, Paul R.,Mahale, Sachin,Chaudhuri, Bhabatosh,Marechal, Jean-Didier,Sutcliffe, Michael J.
, p. 787 - 801 (2007/10/03)
We present the design, synthesis, and biological activity of three classes of tryptamine derivatives, which are non-planar analogues of the toxic anti-cancer agent fascaplysin. We show these compounds to be selective inhibitors of CDK4 over CDK2, the most active compound 9q has an IC50 for the inhibition of CDK4 of 6 M. The Royal Society of Chemistry 2006.
New fascaplysin-based CDK4-specific inhibitors: Design, synthesis and biological activity
Aubry, Carine,Jenkins, Paul R.,Mahale, Sachin,Chaudhuri, Bhabatosh,Marechal, Jean-Didier,Sutcliffe, Michael J.
, p. 1696 - 1697 (2007/10/03)
The first biologically active non-planar analogues of the toxic anti-cancer agent, fascaplysin, have been produced; we present the design, synthesis and biological activity of three tryptamine derivatives.
